12 Best Biotech Penny Stocks to Invest In

Published on March 24, 2024 at 3:54 pm by Usman Kabir in Hedge Funds, News

In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In.

The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in investments in biotech firms as vaccine development for the COVID-19 pandemic became a primary concern around the globe. Following the success of these vaccines, there was a normalization period for the biotech market as macro factors, combined with waning interest in coronavirus vaccines, as well as fewer drug approvals by the drug authorities hit revenues. In 2023, the sector rebounded, jumping back to pre-pandemic levels of growth.

As the market dynamics improve, investments are surging, IPOs picking up pace again, and companies continue to innovate, there is increased optimism around the biotech world in 2024. One indication of this optimism is the performance of biotech giants like GlaxoSmithKline plc (NYSE:GSK), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV) on the stock market. The shares of these firms are up 12%, 29%, and 11% year-to-date respectively. There is an uptick in shareholder activism and mergers and acquisitions activity too.

Investors eager to ride the optimism in the biotech sector this year should carefully look at the growth plans of big biotech companies that are spending billions in research and development to stay ahead of the curve. The comments of Dave Ricks, the CEO of Eli Lilly and Company (NYSE:LLY), can provide some context into this. During the fourth quarter earnings call at the beginning of February, Ricks highlighted the efforts of his company towards increasing the resilience of drug manufacturing and growing top lines through key partnerships.

“In terms of external innovation, in 2023, we continued to complement our pipeline through acquisitions and collaborations. These transactions included the acquisition of DICE Therapeutics, POINT Biopharma, Versanis Bio, Emergence Therapeutics, Mablink Biosciences, Immunitrack, as well as Sigilon Therapeutics. We announced several significant investments in manufacturing, including plans to expand capacity at the company’s Research Triangle Park facility and the two manufacturing sites within the LEAP Innovation Park in Boone County, Indiana. Most recently, we announced plans to construct a new high-tech manufacturing site in Germany. This facility will further expand the company’s global injectable product and device manufacturing network, including for our diabetes and obesity portfolio. Most importantly, this past year, we brought innovative new medicines to patients. In 2023, we received regulatory approvals for Zepbound, Jaypirca, Omvoh, and Ebglyss in the U.S. and in the EU, rather, and an expanded label for Verzenio, and two new indications for Jardiance.

This progress will serve as a foundation to drive top-tier revenue growth and margin expansion over time. we continue to make progress against our strategic deliverables in Q4. Revenue grew 28%, with our new products growing by over $2 billion. Since our last earnings call, we achieved several key pipeline milestones. In addition to the Zepbound and Jaypirca CLL approvals, today, we announced top-line results for the tirzepatide phase 2 SYNERGY-NASH trial, as well as the Verzenio phase 3 CYCLONE-2 trial. Dan will talk more about these updates in his update. In terms of business development, in Q4, we completed the acquisitions of Mablink Biosciences and POINT Biopharma, the latter of which expands our capacity and capability into radioligand therapies. Lastly, we announced a 15% dividend increase for the sixth consecutive year and distributed over $1 billion in dividends in the fourth quarter.”

Our Methodology

The companies that operate in the biotech sector and are priced under $5 per share, as of March 18, were selected through extensive research on Reddit and prominent finance websites. They were then ranked based on hedge fund sentiment. The analyst ratings of each stock are also discussed to provide readers with some context for their investment choices. The hedge fund sentiment around each stock was calculated using the data of around 900 hedge funds tracked by Insider Monkey in the fourth quarter of 2023. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

A laboratory technician researching a sample of cells in a biotechnology laboratory.

Best Biotech Penny Stocks to Invest In

12. Acasti Pharma Inc. (NASDAQ:ACST)

Number of Hedge Fund Holders: 1

Acasti Pharma Inc. (NASDAQ:ACST) is a Canada-based biotechnology company founded in 2002. On February 7, investment advisory Craig-Hallum initiated coverage of Acasti Pharma Inc. (NASDAQ:ACST) stock with a Buy rating and a price target of $6.

Among the hedge funds being tracked by Insider Monkey, Texas-based investment firm ADAR1 Capital Management is a leading shareholder in Acasti Pharma Inc. (NASDAQ:ACST) with 34,532 shares worth more than $99,000.

At the end of the fourth quarter of 2023, 1 hedge fund in the database of Insider Monkey held stakes worth $100,000 in Acasti Pharma Inc. (NASDAQ:ACST).

Just like GlaxoSmithKline plc (NYSE:GSK), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Acasti Pharma Inc. (NASDAQ:ACST) is one of the best biotech penny stocks to invest in.

11. iBio, Inc. (NYSE:IBIO)

Number of Hedge Fund Holders: 2

iBio, Inc. (NYSE:IBIO) provides contract development and manufacturing services to the healthcare industry. iBio, Inc. (NYSE:IBIO) engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis, as well as the EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.

Among the hedge funds being tracked by Insider Monkey, New Jersey-based investment firm Sabby Capital is a leading shareholder in iBio, Inc. (NYSE:IBIO) with 176,748 shares worth more than $242,000.

At the end of the fourth quarter of 2023, 2 hedge funds in the database of Insider Monkey held stakes worth $277,000 in iBio, Inc. (NYSE:IBIO), compared to 1 in the preceding quarter worth $16.

10. Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)

Number of Hedge Fund Holders: 2

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) is a Boston-based biopharma firm founded in 2018. Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) engages in the discovery, development, and commercialization of medicines for serious central nervous system diseases. A lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer’s disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Slate Path Capital is a leading shareholder in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) with 357,880 shares worth more than $1.1 million.

At the end of the fourth quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $2.31 million in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), the same as in the preceding quarter worth $2.30 million.

9. Entera Bio Ltd. (NASDAQ:ENTX)

Number of Hedge Fund Holders: 3

Entera Bio Ltd. (NASDAQ:ENTX) is a biopharma firm that concentrates on the development of orally-delivered therapeutics. In mid-December, investment advisory HC Wainwright maintained a Buy rating on Entera Bio Ltd. (NASDAQ:ENTX) stock with a price target of $10.

Among the hedge funds being tracked by Insider Monkey, New York-based firm Knoll Capital Management is a leading shareholder in Entera Bio Ltd. (NASDAQ:ENTX) with 3.8 million shares worth more than 2.3 million.

At the end of the fourth quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $2.3 million in Entera Bio Ltd. (NASDAQ:ENTX), compared to 4 in the preceding quarter worth $1.8 million.

8. Agile Therapeutics, Inc. (NASDAQ:AGRX)

Number of Hedge Fund Holders: 3

Agile Therapeutics, Inc. (NASDAQ:AGRX) operates as a women’s healthcare firm. Agile Therapeutics, Inc. (NASDAQ:AGRX) researches, develops, and commercializes prescription contraceptive products for women in the United States. A lead product for the firm is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Armistice Capital is a leading shareholder in Agile Therapeutics, Inc. (NASDAQ:AGRX) with 108,000 shares worth more than $210,000.

At the end of the fourth quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $363,000 in EAgile Therapeutics, Inc. (NASDAQ:AGRX), up from 2 in the preceding quarter worth $266,000.

7. ReWalk Robotics Ltd. (NASDAQ:LFWD)

Number of Hedge Fund Holders: 4

ReWalk Robotics Ltd. (NASDAQ:LFWD) is a medical device company that markets robotic exoskeletons for individuals with mobility impairments. On February 28, investment advisory HC Wainwright maintained a Buy rating on ReWalk Robotics Ltd. (NASDAQ:LFWD) stock with a price target of $21.

Among the hedge funds being tracked by Insider Monkey, Nevada-based investment firm Kent Lake Capital is a leading shareholder in ReWalk Robotics Ltd. (NASDAQ:LFWD) with 683,447 shares worth more than $531,000.

At the end of the fourth quarter of 2023, 4 hedge funds in the database of Insider Monkey held stakes worth $905,000 in ReWalk Robotics Ltd. (NASDAQ:LFWD), up from 2 in the preceding quarter worth $11,000.

6. Asensus Surgical, Inc. (NYSE:ASXC)

Number of Hedge Fund Holders: 4

Asensus Surgical, Inc. (NYSE:ASXC) is a medical device company that markets robotics solutions for enhancement of minimal invasive surgery. In mid-November, investment advisory HC Wainwright maintained a Buy rating on Asensus Surgical, Inc. (NYSE:ASXC) stock with a price target of $2.

At the end of the fourth quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $740,000 in Asensus Surgical, Inc. (NYSE:ASXC), the same as in the previous quarter worth $877,000.

Along with GlaxoSmithKline plc (NYSE:GSK), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Asensus Surgical, Inc. (NYSE:ASXC) is one of the best biotech penny stocks to invest in.

Click to continue reading and see 5 Best Biotech Penny Stocks to Invest In.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up